Trial Profile
Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lanreotide as as Volume Reducing Treatment of Polycystic Livers [EXTENSION OF 700242526]
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- Acronyms LOCKCYST-ext
- 28 Mar 2014 New trial record